Literature DB >> 11112133

Airway nitric oxide levels in cystic fibrosis patients are related to a polymorphism in the neuronal nitric oxide synthase gene.

H Grasemann1, N Knauer, R Büscher, K Hübner, J M Drazen, F Ratjen.   

Abstract

Patients with cystic fibrosis (CF) have decreased concentrations of expired nitric oxide (FENO) as compared with healthy individuals. A number of factors, including viscous mucus as a diffusion barrier for airway NO, consumption of NO by bacterial enzymes, and decreased NO production have been hypothesized to account for these low levels of FENO. We examined the relationship between the size of an AAT repeat polymorphism in intron 20 of the NOS1 gene and FENO in 75 patients with CF. Mean FENO was significantly (p = 0.027) lower in CF patients who harbored two alleles with a high number of repeats (>/= 12) than in those who harbored alleles with fewer repeats at this locus (4.0 +/- 0.8 [mean +/- SEM] ppb versus 6.4 +/- 0.9 ppb). Colonization of the airways with Pseudomonas aeruginosa was significantly (p = 0.0358) more common in CF patients with high numbers of AAT repeats in the NOS1 gene. Significant differences between NOS1 genotypes were also observed among patients homozygous for the cystic fibrosis transmembrane regulator delta F508 mutation for FENO (2.3 +/- 0.4 ppb versus 5.3 +/- 0.7 ppb, p = 0.0006), and this was also true for colonization of the airways with P. aeruginosa (p = 0.0147) and Aspergillus fumigatus (p = 0.0221). These data provide evidence that the NOS1 gene is not only associated with the variability of FENO, but also with P. aeruginosa colonization of airways in CF patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11112133     DOI: 10.1164/ajrccm.162.6.2003106

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  23 in total

Review 1.  Cystic fibrosis modifier genes.

Authors:  Jane Davies; Eric Alton; Uta Griesenbach
Journal:  J R Soc Med       Date:  2005       Impact factor: 5.344

Review 2.  Disease modifying genes in cystic fibrosis: therapeutic option or one-way road?

Authors:  Rainer Büscher; Hartmut Grasemann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-10-11       Impact factor: 3.000

3.  Cystic fibrosis-related diabetes: from CFTR dysfunction to oxidative stress.

Authors:  Thierry Ntimbane; Blandine Comte; Geneviève Mailhot; Yves Berthiaume; Vincent Poitout; Marc Prentki; Rémi Rabasa-Lhoret; Emile Levy
Journal:  Clin Biochem Rev       Date:  2009-11

Review 4.  Update on gene modifiers in cystic fibrosis.

Authors:  Joseph M Collaco; Garry R Cutting
Journal:  Curr Opin Pulm Med       Date:  2008-11       Impact factor: 3.155

5.  Nitric oxide synthase 1 as a potential modifier gene of decline in lung function in patients with cystic fibrosis.

Authors:  J Texereau; S Marullo; D Hubert; J Coste; D J Dusser; J Dall'Ava-Santucci; A T Dinh-Xuan
Journal:  Thorax       Date:  2004-02       Impact factor: 9.139

6.  Inducible NO synthase expression is low in airway epithelium from young children with cystic fibrosis.

Authors:  A Moeller; F Horak; C Lane; D Knight; A Kicic; S Brennan; P Franklin; J Terpolilli; J H Wildhaber; S M Stick
Journal:  Thorax       Date:  2006-03-03       Impact factor: 9.139

Review 7.  Arginase and pulmonary diseases.

Authors:  Harm Maarsingh; Tonio Pera; Herman Meurs
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-04-24       Impact factor: 3.000

Review 8.  Chronic pancreatitis and cystic fibrosis.

Authors:  H Witt
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

9.  Exhaled nitric oxide and asthma: complex interactions between atopy, airway responsiveness, and symptoms in a community population of children.

Authors:  P J Franklin; S W Turner; P N Le Souëf; S M Stick
Journal:  Thorax       Date:  2003-12       Impact factor: 9.139

10.  CFTR Modulator Therapies in Pediatric Cystic Fibrosis: Focus on Ivacaftor.

Authors:  Elizabeth L Kramer; John P Clancy
Journal:  Expert Opin Orphan Drugs       Date:  2016-09-13       Impact factor: 0.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.